Lexaria Bioscience Corp - SIC # 2833 - MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS

Ticker Exchange SIC # Website Latest Ticker
LEXX Nasdaq 2833 https://www.lexariabioscience.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Lexaria Bioscience Corp

Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study - Apr 16th, 2024 1:10 pm
Lexaria Awarded New Patents - Apr 2nd, 2024 1:00 pm
Lexaria to Present at The LD Micro Invitational XIV - Mar 21st, 2024 1:20 pm
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer - Mar 14th, 2024 1:20 pm
Lexaria Awards Contract For Next GLP-1 Human Pilot Study - Mar 7th, 2024 1:05 pm
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1 - Mar 5th, 2024 2:05 pm
7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study - Mar 4th, 2024 2:15 pm
Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial - Mar 1st, 2024 1:20 pm
This Lexaria Bioscience Insider Increased Their Holding By 23% Last Year - Feb 18th, 2024 1:46 pm
Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Feb 16th, 2024 9:05 pm
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Feb 15th, 2024 1:00 pm
Lexaria's Submits Investigational New Drug Application - Jan 30th, 2024 1:45 pm
Lexaria Releases Annual Letter from the CEO - Jan 24th, 2024 1:45 pm
LEXX’ Sweet Opportunity in GLP-1s - Jan 22nd, 2024 9:37 am
Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program - Jan 16th, 2024 2:10 pm
Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream - Jan 11th, 2024 1:30 pm
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform - Jan 9th, 2024 1:30 pm
Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide - Jan 4th, 2024 2:05 pm
Lexaria's Investigational New Drug Application Filing Update - Dec 7th, 2023 2:20 pm
LEXX: GLP-1s’ Sweet Opportunity - Nov 30th, 2023 10:51 am